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The gamma interferon (IFN-) enzyme-linked immunospot (ELISPOT) assay is used routinely to evaluate
the potency of human immunodeficiency virus (HIV) vaccine candidates and other vaccine candidates. In order
to compare candidates and pool data from multiple trial laboratories, validated standardized methods must be
applied across laboratories. Proficiency panels are a key part of a comprehensive quality assurance program
to monitor inter- and intralaboratory performance, as well as assay performance, over time. Seven Interna-
tional AIDS Vaccine Initiative-sponsored trial sites participated in the proficiency panels described in this
study. At each laboratory, two operators independently processed identical sample sets consisting of frozen
peripheral blood mononuclear cell (PBMC) samples from different donors by using four blind stimuli. PBMC
recovery and viability after overnight resting and the IFN- ELISPOT assay performance were assessed. All
sites demonstrated good performance in PBMC thawing and resting, with a median recovery of 78% and
median viability of 95%. The laboratories were able to detect similar antigen-specific T-cell responses, ranging
from 50 to >3,000 spot-forming cells per million PBMC. An approximate range of a half log in results from
operators within or across sites was seen in comparisons of antigen-specific responses. Consistently low
background responses were seen in all laboratories. The results of these proficiency panels demonstrate the
ability of seven laboratories, located across three continents, to process PBMC samples and to rank volunteers
with differential magnitudes of IFN- ELISPOT responses. These findings also illustrate the ability to
standardize the IFN- ELISPOT assay across multiple laboratories when common training methods, reagents
such as fetal calf serum, and standard operating procedures are adopted. These results are encouraging for
laboratories that are using cell-based immunology assays to test HIV vaccines and other vaccines.
Most human immunodeficiency virus (HIV) vaccines cur-
rently in development aim to induce cellular immune re-
sponses, since these have been shown previously to temporally
correlate with the containment of virus in infected individuals
and, more significantly, to be crucial in the suppression of virus
in the rhesus macaque model (2, 13, 15, 25). The ability to
measure and quantitate cellular immune responses has been
facilitated through the development of enzyme-linked immu-
nospot (ELISPOT) and flow cytometry assays which determine
the number of antigen-specific cells through surrogate markers
of effector function, such as cytokine production or the degran-
ulation of lytic granules (1, 8, 23, 29), and are more quantita-
tive and less labor-intensive than traditional assays that detect
T-cell responses, such as 51Cr release and lymphoproliferation
assays (19). The gamma interferon (IFN-) ELISPOT assay is
a primary assay employed to measure vaccine immunogenicity
in HIV vaccine clinical trials, in addition to trials in the cancer,
malaria, and tuberculosis vaccine fields (23, 30, 31). Although
data on the performance of the IFN- ELISPOT assay across
multiple laboratories both within and across continents are
critical to the generation of standardized data on vaccine im-
munopotency (14), little published data exist. The IFN- ELISPOT
assay results can demonstrate whether a vaccine is able to
induce a range of immune responses in a particular population,
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therefore justifying further development. The value of stan-
dardized methods for determining vaccine immunopotency
should not be diminished in spite of recent disappointing data
from an HIV vaccine trial in which advancement to a phase IIb
trial was based partly on IFN- ELISPOT data from phase I
and II clinical trials (7, 26). Future modifications to the IFN-
ELISPOT assay may increase its relevance to efficacy testing or
allow it to correlate better with elaborate assays that yield
critical effector functions such as the inhibition of viral repli-
cation (9, 24). The International AIDS Vaccine Initiative
(IAVI), in collaboration with local partners, has developed
good clinical laboratory practice (GCLP) guideline-compliant
clinical trial laboratories at trial units across Europe, Africa,
and India. These GCLP guideline-compliant laboratories can
be used for the comparative assessment of HIV vaccine can-
didates developed by IAVI and other organizations and part-
ners, for example, the Division of AIDS (NIH, Bethesda, MD)
and biotechnology firms, to facilitate the development of an
HIV vaccine (10, 22). As part of the ongoing assessment of
laboratory performance and assay result comparability, IFN-
ELISPOT proficiency panels are conducted regularly at the
IAVI-sponsored laboratories. Such proficiency panels have
also been conducted among laboratories from different orga-
nizations within the HIV vaccine field and have recently been
implemented at laboratories working within the Cancer Vac-
cine Consortium (3, 4, 11). In contrast to published data, the
findings of the present study demonstrate that when standard-
ized training and validated assay methods are followed, the
results of the IFN- ELISPOT assay and the associated han-
dling of test material are notably and highly concordant among
laboratories. These data hold promise for the HIV vaccine
field as a whole and also for cancer, malaria, and tuberculosis
cell-based vaccines. It is possible that comparable data can be
obtained across multicenter trials and continents, facilitating
concordant and, if warranted, accelerated vaccine develop-
ment efforts.
MATERIALS AND METHODS
Participating laboratories. The following laboratories are currently participat-
ing or have previously participated in IAVI-sponsored HIV vaccine trials: (i) the
IAVI Core Laboratory London (hereinafter referred to as the IAVI Core Lab),
Imperial College, London, United Kingdom, (ii) the Centre for Clinical Vacci-
nology and Tropical Medicine (hereinafter identified as Oxford), Oxford Uni-
versity, Oxford, United Kingdom, (iii) the Kenyan AIDS Vaccine Initiative
(KAVI), University of Nairobi, Nairobi, Kenya, (iv) the Ugandan Virus Re-
search Institute (UVRI), Entebbe, Uganda, (v) Contract Laboratory Services
(CLS), Witwatersrand University, Johannesburg, South Africa, (vi) the National
AIDS Research Institute (NARI), Pune, India, and (vii) the Tuberculosis Re-
search Centre (TRC), Chennai, India.
Training of laboratory teams. Prior to commencing studies, whether with an
existing laboratory and staff or with a newly built laboratory and new staff, the
laboratory team enters the IAVI Core training program. In brief, laboratory
teams attend a 2-day basic training course on GCLPs, followed by up to 2 weeks
of in-depth training in IAVI standard operating procedures (SOPs), which in-
clude the isolation, counting, and freezing of peripheral blood mononuclear cells
(PBMC) and the actual ELISPOT assay procedures, among other things (28). A
laboratory training manual is implemented, and after a review of the manual,
each technician is required to successfully complete a written test. Further
training is then provided at the on-site laboratory by an IAVI technician who
covers the same procedures described in the manual, after which the site team is
required to complete both a qualifying test for PBMC isolation and freezing and,
separately, an IFN- ELISPOT qualifying test. Finally, successful laboratory
teams receive a technical audit of laboratory assays every 6 months and are
enrolled in an ongoing quality control program whereby proficiency in PBMC
procedures is reviewed monthly and proficiency in ELISPOT assay procedures is
reviewed using the negative and positive control data generated in ongoing
clinical trials. The laboratories are also enrolled in a GCLP accreditation pro-
gram (28).
Proficiency panel design. Supplies for one to two proficiency panels are dis-
tributed every year. To date, sample sets for four proficiency panels have been
submitted to a number of laboratories, and data from the first three panels have
been evaluated (Table 1). In brief, the panel sample set consists of duplicate
frozen PBMC samples that are thawed and exposed to blind stimuli consisting of
a mock stimulus; a mixture of 32 influenza virus, Epstein-Barr virus (EBV), and
cytomegalovirus (CMV) peptides (CEF peptides); a pool of CMV pp65 15-mer
peptides; and phytohemagglutinin (PHA; Sigma, Poole, Dorset, United King-
dom). The CEF peptides are a panel of 32 8- to 10-amino-acid peptides encom-
passing epitopes from influenza virus, EBV, and CMV designed to cover diverse
major histocompatibility complex class I genotypes; responses are detected in
approximately 70% of healthy individuals in Africa, Europe, and the United
States (5, 20; also data not shown). The CEF and CMV peptides were synthe-
sized to 90% purity (Anaspec Inc., CA). Two operators each performed thawing
and, for panels 1 and 2, repeat testing on two occasions, with results submitted
to an independent statistician for evaluation. IAVI SOPs and proficiency panel
work instructions were followed, and all procedures were performed under
GCLP conditions, as described previously.
PBMC specimen handling. PBMC were obtained from healthy HIV-seroneg-
ative donors through the United Kingdom National Blood Transfusion Service
(Colindale) for panels 1 (six samples) and 2 (three samples) and from the South
African Blood Transfusion Service under a local ethics body-approved blood-
drawing protocol for panel 3 (eight samples). The 17 PBMC samples came from
17 different donors. All PBMC were isolated, counted, and frozen by following
IAVI SOPs. The PBMC were isolated using Ficoll and density gradient centrif-
ugation and counted with an automated cell counter. Three counters were used:
the Z1 Coulter Counter (Beckman Coulter, United Kingdom), the Vi-CELL
counter (Beckman Coulter, United Kingdom), and the Guava personal cell
analysis system (Guava Technologies, Hayward, CA). Viability was assessed by
using a hemocytometer and trypan blue for counts by the Z1 Coulter Counter.
Samples were frozen at 10 million viable PBMC per vial in a rate-controlled
freezer (Kryo model no. 560-16; Planer, United Kingdom). PBMC were stored in
vapor-phase liquid nitrogen, and shipment to participating laboratories was per-
formed using temperature-monitored cryogenic shippers (Taylor Wharton
TABLE 1. Design of proficiency panels 1 to 3
Panel Participatinglaboratories
No. of PBMC
samples Plate type(s) Counting instruments employed (no. of labs)
a Stimuli
1 Core, Oxford, CLS,
KAVI, UVRI
6 1 Self-coated Z1 Coulter Counter (4), hemocytometer (1) Mock; HIV, CEF, and
CMV peptides;
PHA
2 Core, Oxford, CLS,
KAVI, UVRI,
NARI
3 1 Precoated, 1 self-coated Z1 Coulter Counter (1), hemocytometer (1),
Vi-CELL XR counter (3), Guava counter
(1)
Mock, CEF and CMV
peptides, PHA
3 Core, Oxford, CLS,
KAVI, UVRI,
NARI, TRC
8 1 Precoated, 1 self-coated Z1 Coulter Counter (1), hemocytometer (1),
Vi-CELL XR counter (4), Guava counter
(1)
Mock, CEF and CMV
peptides, PHA
a To obtain viable cell counts with the Z1 Coulter Counter, a hemocytometer and trypan blue staining were also used.
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CX500; Jencons, United Kingdom). Following receipt, the PBMC continued to
be stored in vapor-phase liquid nitrogen until use. Prior to use, the PBMC were
thawed by being warmed in a water bath at 37°C until one small ice crystal
remained and then washed in RPMI medium–20% fetal calf serum (FCS) and
allowed to rest overnight in RPMI medium–20% FCS at 1.5 to 2 million
PBMC/ml in an atmosphere of 5% CO2 at 37°C. The following morning, viable
cells were counted and placed onto the ELISPOT assay plates. All PBMC counts
and recovery and viability results were recorded on batch records.
ELISPOT assay. The IFN- ELISPOT assay was performed as described
previously (22). In brief, 96-well Multiscreen HTS IP plates (MSIP4510; Milli-
pore, United Kingdom) were incubated overnight with 10 g/ml of clone 1-D1K
mouse anti-human IFN- monoclonal antibody (Mabtech, Sweden). The next
day, after being washed and blocked with RPMI medium–10% FCS, the PBMC
were plated at 2  105 viable PBMC per well and stimulated in quadruplicate
according to the ELISPOT templates provided. Blind stimuli included a mock
stimulus (RPMI medium–10% FCS with dimethyl sulfoxide [DMSO] to give a
final concentration per well of 0.45% DMSO) to control for DMSO included in
the peptide stimuli, CEF and CMV peptides at 1.5 g/ml, and PHA (Sigma,
Poole, Dorset, United Kingdom) at 10 g/ml. Following overnight incubation at
37°C and 5% CO2, the production of IFN- was assessed by the addition of 100
l of 1-g/ml filtered biotinylated clone 7-B6-1 mouse anti-human IFN- anti-
body (Mabtech, Sweden) for 2 to 4 h, the addition of ABC peroxidase-avidin-
biotin complex (Vector Laboratories, Burlingame, CA) for 1 h, and development
with filtered AEC (3-amino-9-ethylcarbazole) substrate solution (Vector Labo-
ratories, Burlingame, CA) for 4 min. Plate results were read using an automated
AID ELISPOT reader (AutoImmun Diagnostika, Germany). The ELISPOT
data are expressed as the numbers of spot-forming cells (SFC) per million
PBMC.
Statistical analysis. Analyses of the recovery and viability results for thawed
PBMC, the numbers of SFC per million PBMC, and the coefficients of variation
(CV) of results were performed by the EMMES Corporation (Rockville, MD).
The signed-rank test was used for paired observations (e.g., comparisons be-
tween operators), and the Kruskal-Wallis test was used for comparing multiple
groups (e.g., samples within each panel). Measures of correlation are based on
Spearman’s correlation coefficient.
RESULTS
Recovery and viability of PBMC. All PBMC were received at
the participating laboratories at a temperature below 170°C.
Two operators in each laboratory independently recorded the
total number of viable cells following thawing and overnight
resting, in addition to the percent viability and the calculated
recovery percentage (Fig. 1). All recordings were received ex-
cept those from one laboratory which did not provide viability
data for panels 1 and 2. The median values (and ranges) for
recovery were 81.2% (46 to 163%) in the first panel, 96.3% (60
to 155%) in the second panel, and 69.8% (35 to 170%) in the
third panel.
Comparisons between donors. The Kruskal-Wallis test re-
sults showed variability in recovery rates between PBMC sam-
ples from different donors and were significant in panels 1 (P
0.0005) and 3 (P  0.0013) and borderline in panel 2 (P 
0.0657). This outcome may relate to natural variation in the
propensity of cells for freezing and thawing or to the large
volumes of blood handled (approximately 200 to 500 ml) in the
processing blood bank samples, leading to inaccurate counts
upon freezing. Data from the IAVI partner laboratory network
revealed a median recovery of 70% (median viability of 92%)
from 992 clinical trial samples frozen during 2006, of which the
common blood draw volume was between 40 and 80 ml of
blood (some of these data are shown in Table 2; also see
below). No difference was seen between donors in the viability
percentages (P, 0.23 for each of the three panels), which
ranged from 80 to 100%, with medians of 95, 96, and 95% for
panels 1, 2, and 3, respectively.
Comparisons between sites. Significant differences between
sites in the total recovery of viable cells (P values of 0.0005,
0.0079, and0.0001 in panels 1, 2, and 3, respectively) and also
the viability of PBMC (P values of 0.0050, 0.0003, and0.0001,
respectively), were noted (Fig. 1). This finding may relate to
the difference in the counting methods employed at the sites
(Table 1), since it has been reported previously that the levels
of viability determined by automated counters are lower than
that determined by manual counting (12).
FIG. 1. Recovery and viability of thawed rested PBMC at participating laboratories in each proficiency panel. The recovery is indicated as the
percentage of viable thawed cells recovered relative to the number of viable cells frozen. PBMC were cryopreserved in aliquots of 10 million; thus,
the recovery of 6 million viable PBMC would be 60% recovery. The viability of the total PBMC fraction following thawing and resting is indicated.
Each point represents a single thawed sample. Boxes represent the interquartile ranges, and horizontal lines within the boxes represent the
medians. Vertical bars extend to the largest observed value within 1.5 times the interquartile range. Laboratories listed on the x axes are identified
in Materials and Methods.
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Comparisons between operators. To compare the observa-
tions of operators at each site, the paired differences in recov-
ery and viability for each donor were tested using Wilcoxon’s
signed-rank test. Recovery data differed between operators at
one lab in panel 1 (P 0.031) and at three labs in panel 3 (P
0.0156, 0.0078, and 0.0078). The viability percentages differed
between operators at two labs in panel 1 (P  0.031 for both)
and one lab in panel 3 (P  0.0156). With samples from only
three volunteers, panel 2 had very low statistical power, and no
differences between operators were observed.
Correlation with ELISPOT assay responses. Overall, there
was a statistically significant though not very strong correlation
(20.5%; P  0.0067) between the percentages of viability and
the magnitudes of PHA responses in the ELISPOT assay.
Among panels 1, 2, and 3, the correlations were inconsistent in
magnitude and direction, being 19% (P  0.201), 49% (P 
0.006), and 29% (P  0.005), respectively. Similarly, there was
a weak though statistically significant negative correlation
(24.4%; P  0.0007) overall between recovery rates and
magnitudes of CMV responses in the ELISPOT assay. Again,
the correlations were inconsistent, being 0% (P  1.0), 44%
(P  0.008), and 26% (P  0.012), respectively, for panels 1,
2, and 3. No other correlations were observed.
ELISPOT assay performance. Two operators per laboratory
independently set up each ELISPOT assay by following the
SOPs and template instructions for adding the blind stimuli.
Responses for each donor sample in each laboratory to the
different stimuli are expressed as the numbers of SFC per
million PBMC and are shown in Fig. 2. Mock (i.e., background
or medium) responses are the well counts, whereas CMV,
CEF, and PHA responses are the well counts after the sub-
traction of mock response values. Only 3 (1%) of the 323
responses to the mock stimulus were above 55 SFC/106 cells,
indicating an excessive background count that would result in
assay failure and subsequent retesting of the sample in present
IAVI clinical trials. For the IAVI proficiency panels in the
present study, the mean background level at the seven sites
ranged from 2.3 to 13.6 SFC/106 PBMC and was 7.7 	 15.2
(standard deviation [SD]) overall. If the three specimens with
55 SFC/106 PBMC are excluded, then the mean background
level 	 SD was 6.6 	 8.0 SFC/106 PBMC.
The CEF and CMV stimuli allow the assessment of concor-
dance in the magnitude of antigen-specific responses from
donor PBMC across laboratories and, furthermore, for a given
definition of a response classification (e.g., nonresponder or
responder), the issue of whether responses from different lab-
oratories would be classified equally.
The variation across laboratories in the responses of each
donor sample to CEF peptides is shown in Fig. 2B. In general,
the responses from the different labs are similar, with a range
of about half a log for each sample. However, the figure also
shows that any response classification (a horizontal line drawn
from any point on the y axis) would result in at least one
sample falling into more than one category. In IAVI clinical
trials, the definition of CEF positivity is a response of 38
SFC/106 cells from multiple samples evaluated over time. By
this definition, the data across laboratories show 2 samples (no.
4 and 13) with only negative responses, 2 samples (no. 11 and
14) with mostly negative responses, one sample (no. 9) with
mostly positive responses, and the remaining 12 samples with
all positive responses. In panel 1, five of the six lowest CEF
responses were analyzed by the same operator. Further inves-
tigation revealed that the operator had previously used only
fresh PBMC for ELISPOT assays and had little experience
with thawing PBMC. Revised instructions and training on the
TABLE 2. Comparison of recovery and viability results for PBMC thawed at proficiency panel sites for panel participation or at the IAVI
Core Lab for assessment of immunological responses from clinical trial specimens
Specimen type and site No. ofsamples














CLS 34 77 23 75 50 120 91 3.9 91 82 95
TRC 16 65 25 64 35 121 95 2.1 96 90 98
Core lab 34 91 25 83 60 142 95 2.7 96 89 98
KAVI 34 81 28 73 50 136 91 4.4 92 81 98
NARI 22 91 21 89 58 127 98 1.6 98 96 100
Oxford 33 88 27 78 56 130 94 3.4 96 86 98
UVRI 34 76 26 69 46 123 96 1.5 96 93 99
Total 207 82 26 78 48 130 94 3.9 95 86 99
Clinical trial specimens
CLS 512 62 33 60 20 120 90 7.5 91 75 98
TRC 431 61 18 60 33 93 93 4.4 93 86 98
KAVI 426 74 21 70 40 110 92 4.4 93 85 97
NARI 233 77 30 70 40 130 91 6.1 93 77 97
Oxford 121 58 21 60 20 90 93 7.3 95 82 98
UVRI 369 65 17 60 40 90 92 6.0 93 82 97
Total 2,092 66 25 65 30 110 91 6.0 93 81 97
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use of cryopreserved PBMC were provided for the subsequent
panels.
The variation across laboratories in the responses of each
donor sample to CMV pp65 is shown in Fig. 2C. Again, the
range of responses is about half a log per sample (except for
sample 4 from panel 1), showing the consistency in results
across labs. If CMV-positive responses are arbitrarily defined
as those with 50 SFC/106 cells, then the CMV results would
be categorized as six negative samples, two borderline re-
sponders (samples 4 and 9), and nine positive samples.
PHA responses are shown in Fig. 2D. The majority are
1,000 SFC/106 cells, as expected, except for some panel 3
responses of 450 SFC/106 cells and four panel 1 responses of
108 SFC/106 cells. Three of the low panel 1 responses were
measured by the same operator who obtained five of the six
lowest CEF responses.
ELISPOT assay variation in each panel. In IAVI trials, a
typical analysis of ELISPOT data uses the mean count from
replicate wells for each peptide on a plate. Since the number of
replicates is generally small (usually three or four), the mean
can easily be influenced by extreme values. Thus, as one of the
criteria for defining positive responses, IAVI requires that the
variation among the replicates be small relative to the mean.
That is, the CV, defined as the SD divided by the mean, must
not be greater than 70%. Since the three panels were con-
ducted in sequence, with an interval of 6 to 9 months between
each one, we wanted to investigate whether there was any
change in the CV across quadruplicate wells. Typical examples
are shown in Fig. 3. Clearly, as the mean spot counts increased,
the CV decreased; it remained below 70% (in general 30%)
for counts greater than 50 SFC per 106 cells, and there was
little variation among the three panels.
Concordance between HIV type 1 vaccine trial responses
from two laboratories. The conducting of ELISPOT assay pro-
ficiency panels is a critical tool for ensuring comparable labo-
ratory performances both within and across networks and also
for identifying and troubleshooting reasons for differences, if
they exist. When dealing with actual volunteer samples during
a clinical trial, laboratory personnel may be under increased
pressure from the prioritization of work, the time at which
samples are drawn, or late changes to scheduled visits. Table 2
shows the viability and recovery of PBMC thawed at the pro-
ficiency panel laboratories for panel participation (also see Fig.
1) and at the IAVI Core for the assessment of immunological
responses from clinical trial specimens. Excellent recovery and
viability of the PBMC shipped to the sites and of the PBMC
cryopreserved on site and then shipped to the IAVI Core were
seen. One vaccine trial in which the same PBMC samples were
tested both fresh following blood drawing on site at KAVI in
Nairobi and frozen after shipment to the IAVI Core in London
FIG. 2. Laboratory ELISPOT spot-forming unit (SFU) counts for each donor PBMC sample in response to specific stimuli in panels 1 to 3.
SFU counts shown for CEF and CMV peptides and PHA were determined by subtracting background values and are presented per 106 PBMC.
Each box plot represents all results for a single donor. A single observation represents the mean response from one lab and one operator.
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provided ideal data with which to compare and assess perfor-
mances in real time under real conditions (J. Bwayo et al.,
unpublished results). Trial donor PBMC samples assessed in
the two laboratories exhibited concordant responses (Spear-
man’s correlation coefficients ranged from 50 to 81% for six
HIV peptide pools [P, 0.05 for all but one]), despite the use
of either freshly isolated or thawed cryopreserved PBMC, pro-
viding further assurance that proficiency panel data are useful
to indicate actual trial performance. These two laboratories
also had concordant results in the proficiency panels (Fig. 2 and
3). Figure 4 shows typical examples of IFN- ELISPOT assay re-
sponses to CEF and HIV peptide pools used in the trial. There
is a slight trend toward fresh samples scoring higher than
frozen samples for vaccine-induced responses (those to HIV
peptide pools), in contrast to CEF responses, which likely
represent memory T-cell responses to previous CMV and EBV
exposure. In addition, the CEF response should be entirely
CD8 restricted (8- to 10-mer peptides) whereas the responses
to Env, Pol, and Nef are mediated by both CD4 and CD8 T
cells (15-mer peptides).
DISCUSSION
The IAVI Core and partner laboratories regularly partici-
pate in ELISPOT assay internal proficiency panels and exter-
nal quality assurance (EQA) panels, with the aim of comparing
their abilities to process PBMC, to evaluate the CMV and CEF
ELISPOT assay responses of donor samples, and to identify
and rectify any technical issues. Using standardized equipment
and instructions and SOPs, with the only difference being the
method of cell counting, the laboratory teams conducting the
three panels analyzed to date have yielded remarkably concor-
dant ELISPOT assay results. We have shown that IAVI part-
ner laboratories are able, in the majority of cases, to success-
fully categorize samples across a range of low, medium, and
high spot counts, to achieve low background values, and to
correctly identify nonresponders. Cell viability and recovery
results were much tighter and the minimum recoveries were
much higher than those reported previously. These laborato-
ries, with one exception, had never done ELISPOT testing
prior to its implementation to support IAVI-funded clinical
trials.
These types of results have not been achieved in previous
proficiency panels among laboratories across organizations,
either in the HIV vaccine field or in other fields such as cancer
research (4, 11). The ability to determine whether a response
is either positive or negative is critical for assessing vaccine
immunopotency, i.e., the ability to induce an immune response
(7, 8). When multiple laboratories are able to categorize sam-
ples in a consistent manner, comparative assessment and de-
cision making for multiple vaccine candidates become easier
both across and within networks. The use of multiple labora-
tories will accelerate the testing of vaccines and, hence, vaccine
development and will furthermore provide robust ELISPOT
data capable of distinguishing different response rates and
magnitudes. The salient details that enabled concordant per-
formances across seven laboratories based on three continents,
an objective not achieved previously, were the standardized
methods employed and the operators’ familiarity with these
methods (11). These included not only the methods and re-
agents used in the assay but also the ELISPOT assay reader
model and settings, which are critical for counting spots with
the same morphology (12). Methods of shipping, storage,
thawing, and overnight resting of PBMC have been shown
previously to affect measures of antigen sensitivity and assay
performance (4, 6, 8, 17, 18, 27). Indeed, other panels have
shown an improvement in sensitivity and general performance
when some of these factors are standardized in successive
panels (11).
In addition to the standardized methods used, another sig-
nificant difference affecting performance in these panels versus
other panels was the quality systems of participating laborato-
ries. All IAVI partner laboratory personnel involved in the
testing of IAVI- or other network-sponsored HIV vaccines
undergo carefully integrated training, operate in a GCLP en-
vironment, and follow detailed SOPs that necessitate active
FIG. 3. The CV between replicate wells for two of the laboratories that participated in all three panels are shown, in relation to grouped
ELISPOT SFC counts for CEF and CMV peptides and PHA. The dotted line represents a CV of 70%. Counts were determined by subtracting
background values and are presented per 106 PBMC. Within each subgroup, there are up to three box plots, representing panels 1 to 3, respectively.
152 BOAZ ET AL. CLIN. VACCINE IMMUNOL.
interpretation of results and recording of incubation times.
These aspects result in a highly controlled environment that
may not be achieved in all laboratories. In support of this
prospect, it is prudent to highlight that operator variation, a
well-known factor in ELISPOT assay variability, was not of
note in these panels (12), although consistent differences in
ELISPOT assay counts from the two operators at one labora-
tory in panel 1 and another in panel 3 were obtained (data not
shown). The background values observed in the panels de-
scribed in this study were very low, with an overall mean of 6.6
SFC/106 cells (determined by excluding 3 samples, of the total
of 323, which had 55 SFC/106 cells), whereas in other
proficiency panels, numerous laboratories produced high
background values that clearly affected the determination of
positive responses (11). A possible explanation for high
background levels may be the serum source. At IAVI, a stan-
dardized FCS is purchased in a large volume after prescreen-
ing to ensure that both low background and antigen-specific
responses are supported.
Differences across laboratories with respect to viable cell
counts were noted, even though the counts were obtained from
the same donor PBMC isolated from the same blood draw.
These differences were due most likely to the use of different
automated counting equipment, some of which performed in-
tegrated viable cell counts and some of which did not. The
number of laboratories per panel using each particular counter
does not permit the statistical evaluation of this variable,
though we note that the different viable cell counts did not in
general correlate with the SFC values, indicating that perhaps
differences in recovered cells were related to disparity in the
numbers of cryopreserved PBMC per vial. In particular, cell
counting should be standardized across laboratories and the
use of automated counters should be encouraged. The cell-
counting procedures for these automated counters can be val-
idated and carried out under GCLP guidelines. We looked at
the CV among replicate wells as a measure of the perfor-
mances of those laboratories that participated in all three con-
secutive panels. No marked decrease or improvement in the
CV was noted, probably due to the optimized methods in use
since the first panel was conducted. This conclusion is sup-
ported by the values observed in the first panel, in which 36
(95%) of the 38 CEF and CMV ELISPOT assay counts in the
range of 50 to 250 SFC/106 cells had a CV below 50%, which
is low for a biological assay of low magnitude (16, 21).
Upon the review of the panel 1 data, it was revealed that one
operator was inexperienced at thawing frozen PBMC and en-
FIG. 4. Spot-forming unit (SFU) counts, determined by subtracting background values, for samples isolated at all postvaccination time points
and assessed for responses to HIV peptide pools during an HIV vaccine trial. Freshly isolated PBMC were used in Nairobi, and responses (y axes)
were correlated to those of thawed frozen PBMC in the assay performed at the IAVI Core in London (x axes). Spearman’s correlation coefficient
is also shown and is statistically significant for all peptide pools (P is 0.05 for all except Pol B1, for which P is 0.0562). Regression lines were
calculated only for positive responses (i.e., a response of 0 SFU after the subtraction of background values).
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countered difficulties. As a result, improved instructions relat-
ing to these aspects, often considered routine in most labora-
tories, were provided. In the subsequent panels, no difficulties
with thawing were observed.
Regular independent quality assurance testing is a key com-
ponent of the quality systems required for any test being con-
ducted by IAVI-sponsored GCLP guideline-compliant labora-
tories. Given that there is no independent EQA program such
as the United Kingdom National External Quality Assessment
Service CD4 program for ELISPOT assays at present, the
proficiency panel provides a step toward such assurances
within the IAVI program. In addition, frozen samples from all
clinical trial sites are routinely shipped to the IAVI Core in
London for independent testing. There remains a need across
multiple programs for EQA panels.
The disappointing lack of efficacy of the Merck adenovirus-
based HIV vaccine candidate led previously to a discussion
concerning the utility of the IFN- ELISPOT assay (26). It is
worth noting that the performance and robustness of this assay
continue to make it a valid assay of T-cell vaccine immunopo-
tency in early clinical development (7). This paper provides
encouraging evidence that when applied using standardized
methods, the ELISPOT assay is sensitive and discriminatory
and that highly concordant results can be obtained across lab-
oratories located on three different continents. This finding is
encouraging for multicenter vaccine trials across disciplines
and also for the possibility of obtaining comparable results in
the detection and discernment of cellular immune responses of
differential magnitudes.
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